Navigation Links
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

stration trials and has the potential to be the first Hsp90 inhibitor to reach the market. Our TIME registration program for tanespimycin in patients with multiple myeloma is on track to be initiated in the third quarter of 2007, which will be a major milestone for our company."

Phase 2 Tanespimycin Melanoma Trial

Tanespimycin binds to and inhibits the activity of Hsp90. Hsp90 inhibition results in the degradation of a variety of RAF family proteins, including mutant BRAF. As the majority of melanomas have activation of the BRAF-MAP kinase pathway, it is postulated that tanespimycin interrupts the MAP kinase pathway and may lead to clinically significant anti-melanoma effects. The Phase 2 trial of tanespimycin was designed as a multi-center two-stage Simon design study; continuation to the second stage required at least 1 of the first 9 patients to have a progression-free survival (PFS) time of at least 24 weeks, the primary endpoint of the trial. Eligible patients had stage M1 melanoma, measurable/unresectable disease and had progressed within 3 months of study entry with no more than 1 prior chemotherapy treatment for metastatic melanoma. Tanespimycin was administered at a dose of 275 mg/m2 by 1-2 hour intravenous infusion 2 times per week every 2 out of 3 weeks until disease progression or toxicity. 20 patients have been enrolled, and efficacy data are available on 14 evaluable patients. One of the 6 evaluable patients with a BRAF mutation (V600E) showed evidence of anti-melanoma activity. An additional patient with BRAF mutation continues on study but is too early to assess for efficacy at present. The safety profile has been manageable and included predominantly Grade 1 and 2 toxicities (constitutional and gastrointestinal symptoms). Grade 3 or 4 toxicity, which was generally manageable and reversible, resulted in treatment discontinuation in 2 patients. Accrual is continuing toward the goal of enrolling a total of 30 evaluable patients (with cont
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:10/1/2014)... 2014 The Cardinal Health 2014 digital ... can learn about the company,s fiscal year ... the health care continuum by accessing the ... Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... chief executive officer,s letter to shareholders, the ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... service provider for the medical industries, announced today the expansion of ... New York City . genae Americas was incorporated in ... strategically centered in one of the highest concentrations of medical innovation ... Kassab , President at genae Americas. "The expansion of genae from ...
(Date:10/1/2014)...  Express Scripts (NASDAQ: ESRX ) today ... Medicare ® Prescription Drug Plans (PDP) will offer ... WAG ) (NASDAQ: WAG ), helping ...  for their Medicare dollars. Medicare beneficiaries who ... or Choice plans for 2015 can save ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2genae Opens Offices in New York City 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... EAST RUTHERFORD, N.J., Nov. 1, 2011 Cambrex Corporation ... 2011 financial results will be released on Thursday, November ... The Company will host a conference call to discuss ... Conference CallWhen: , Friday, November 4, 2011 at 8:30 ...
... 2011 Takeda Global Research & Development ... Drug Administration (FDA) has assigned a Prescription Drug User ... for the review of its investigational type 2 diabetes ... combines alogliptin with pioglitazone in a single tablet.   ...
Cached Medicine Technology:Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 2Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 3
(Date:10/1/2014)... scientists has shown that more than 80 per cent ... , The study found that medicines called ,JAK inhibitors, ... mutation that is present in more than 80 per ... used, or are in clinical trials, for diseases including ... Bowel cancer is the second-most common cancer in Australia ...
(Date:10/1/2014)... of the human eye, the brain of a rat ... new technology, says a QUT leading robotics researcher. ... Faculty says the new study uses new computer algorithms ... buildings or tunnels. , "This is a very Frankenstein ... two halves of a thing together because we,re taking ...
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... 2014 Marriagelifeinsurance.com has released a ... for retired couples. , Senior citizens can purchase ... for their loved ones. A joint policy is cheaper, ... pass away. , Life insurance can be used ... can even be purchased online, as the application process ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2
... , , AUSTIN, Texas, ... processing expert, ThermoGenesis Corp., to deliver the most sophisticated point ... innovative MarrowXpress(TM) (MXP(TM)) System defines a new standard for isolation ... MXP System consistently yields high (> 90%) mononuclear cell recovery ...
... Global health organization PSI helps contestants spread HIV prevention messages throughout ... 21 The Miss Universe contestants continued preparations for Sunday night,s ... condoms to test their strength and playing "Wild Fire Infection" games ... are part of an HIV peer education workshop designed by PSI ...
... , , KUALA LUMPUR, ... Technologies (ICT) is essential for modern healthcare delivery systems if ... and improve patient safety. , , (Logo: ... years, the acquisition of computer technologies by healthcare organizations has ...
... treatment to thousands who need it, experts say ... with patient and therapist texting each other in real-time ... of patients new access to much-needed treatment, researchers say. ... of research and practice involving technology-based treatments for depression ...
... , , , ... (Nasdaq: HTWR - ASX: HIN) today announced that HeartWare has surpassed ... marking an important early enrollment milestone. , , ... at the Texas Heart Institute in Houston, Texas by O.H. Frazier, ...
... N.Y. The Bioproduction Facility at Cornell University has ... vaccinethat will be used in clinical trials for patients ... was developed as a partnership between The Ludwig Institute ... trial is being conducted at New York University Medical ...
Cached Medicine News:Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 2Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 3Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 2Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 3Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 2Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 3Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 4Health News:Web-Based Psychotherapy Can Work 2Health News:Web-Based Psychotherapy Can Work 3Health News:HeartWare International Surpasses 50 Implants in the US 2Health News:HeartWare International Surpasses 50 Implants in the US 3Health News:Cornell makes cancer vaccine for clinical use 2Health News:Cornell makes cancer vaccine for clinical use 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: